Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

CLVS - Clovis Oncology

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by T0rm3nted, Apr 8, 2016.

  1. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,853
    Likes Received:
    1,921
    Clovis Oncology (CLVS) is a small pharmaceutical company which mainly markets products for treatment in oncology. Depomed was founded in 2009 and is headquartered in Dover, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline.
     
    TomB16 likes this.
  2. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,853
    Likes Received:
    1,921
    CLVS down over 17% today.
     
  3. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,853
    Likes Received:
    1,921
    Clovis Oncology (CLVS) Approval Less Likely But Possible

    Mizuho analyst, Eric Criscuolo, thinks the FDA's briefing documents for Clovis Oncology's (NASDAQ: CLVS) April 12 rociletinib AdComm meeting raised numerous issues and concerns for the drug's approval. "It's ugly, but we think the drug could still get approved". No change to Neutral rating or $21 PT.

    The FDA voiced its displeasure over the handling of efficacy data, dose reductions, and recommends a Boxed Warning for QTc. The FDA is asking its advisory panel to vote on one question: "Should the results of the randomized clinical trial (TIGER-3) be submitted before FDA makes a regulatory decision on this application?" TIGER-3 is comparing rociletinib versus chemotherapy, potentially a 2018 event, meaning approval could be a few years away.

    The FDA highlighted a few key questions:

    1) Is the activity of rociletinib reasonably likely to predict clinical benefit and superior to available therapy?

    2) Is the recommended dose of 625 mg BID supported by the data?

    3) Are the risks (particularly QTc) acceptable?

    4) Has the dose modification strategy to been adequately characterized? FDA raised concerns about all of these areas.

    Shares of Clovis Oncology closed at $19.17 yesterday.
     
  4. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
    Massive move and +30% close!!!

    Clovis shares jump as FDA grants priority review to cancer treatment
    http://www.marketwatch.com/story/cl...priority-review-to-cancer-tratment-2016-08-23


    Clovis Oncology Inc. CLVS, +27.24% shares ticked higher after hours Tuesday following a big jump in the regular session as the Food and Drug Administration accepted a marketing application for the company's ovarian cancer treatment and granted it a priority review process. Clovis shares advanced 1% to $23.25 after hours, following a 23% rally in the regular session. The FDA is expected to make a decision on the application by Feb. 23, 2017. Studies of Clovis's treatment rucaparib showed 54% of patients with recurring ovarian cancer responded to the treatment.
     
  5. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
    I swear there are two biotech movers like this each day for the past week!

    Which one will run tomorrow?
     
  6. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
    Lets see if this holds up today again.
     
  7. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
    Big move this moring, coming up on new 52wk highs!
     
  8. LloydWCoutee

    LloydWCoutee Active Member

    Joined:
    May 4, 2016
    Messages:
    724
    Likes Received:
    58
    Credit Suisse analyst: $CLVS could be worth $35-$41 per share on operational synergies, and $52-$55 per share with leveraged tax benefits.
     
  9. bigbear0083

    bigbear0083 Content Manager
    Staff Member

    Joined:
    Mar 29, 2016
    Messages:
    19,334
    Likes Received:
    6,769
    big loser this morning -30% on the open ... coming into the daily 50sma

    [​IMG]
     
  10. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,853
    Likes Received:
    1,921
    Looks like there were some deaths in some of the patients:

    Clovis Oncology Inc (NASDAQ:CLVS) investors are heading for the hills after the cancer drug maker announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib, a third-line treatment of ovarian cancer patients with BRCA-mutated tumors, at the 2016 ESMO Congress in Copenhagen. On the negative side, the company disclosed that nine patients had adverse events that led to death, of which 8 were due to disease progression.

    http://www.smarteranalyst.com/2016/...-heres-clovis-oncology-inc-shares-falling-28/
     
  11. LloydWCoutee

    LloydWCoutee Active Member

    Joined:
    May 4, 2016
    Messages:
    724
    Likes Received:
    58
    will be funny if it go green
     
  12. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    6,853
    Likes Received:
    1,921
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Chardan Capital Mkts
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Sell
    Previous Price Target: N/A
    Current Price Target: $15
     
  13. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
    Big technical break out today!
     
  14. Gambit

    Gambit Active Member

    Joined:
    Oct 16, 2016
    Messages:
    704
    Likes Received:
    62
  15. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
  16. Charles Noble

    Charles Noble Well-Known Member

    Joined:
    Jun 6, 2017
    Messages:
    203
    Likes Received:
    277
    Very predictable with no Monday BO. This will flounder a couple points here and there. The by end of week, new high. Go long for 120+
     
    TomB16, Jack Levy and fidelgeorge like this.
  17. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    6,833
    Likes Received:
    1,869
    Up and over $15
     
    TomB16 likes this.

Share This Page